Forsta AP Fonden trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 9.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,800 shares of the biopharmaceutical company’s stock after selling 2,800 shares during the period. Forsta AP Fonden’s holdings in Alnylam Pharmaceuticals were worth $5,168,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 9.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after acquiring an additional 1,017 shares during the last quarter. MetLife Investment Management LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $1,268,000. Panagora Asset Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 96.4% in the 1st quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Alnylam Pharmaceuticals by 21.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock worth $10,786,000 after purchasing an additional 10,892 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Alnylam Pharmaceuticals by 1.2% during the first quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock worth $29,601,000 after buying an additional 2,111 shares in the last quarter. 94.43% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued at approximately $5,902,303.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Yvonne Greenstreet sold 7,615 shares of the company’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the sale, the chief executive officer now owns 30,332 shares in the company, valued at approximately $5,902,303.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Akshay Vaishnaw sold 2,392 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $465,459.28. Following the completion of the transaction, the president now owns 17,890 shares of the company’s stock, valued at $3,481,215.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,299 shares of company stock valued at $2,782,442. 1.40% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Alnylam Pharmaceuticals Price Performance
Shares of ALNY stock opened at $192.68 on Friday. The company’s fifty day moving average price is $195.76 and its two-hundred day moving average price is $206.63. The firm has a market capitalization of $23.99 billion, a P/E ratio of -22.17 and a beta of 0.48. Alnylam Pharmaceuticals, Inc. has a 12 month low of $135.46 and a 12 month high of $242.97.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.57. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The firm had revenue of $319.29 million during the quarter, compared to the consensus estimate of $312.53 million. During the same quarter in the prior year, the business posted ($2.00) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 49.7% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.52 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Recommended Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
- 3 Large Semiconductor Makers Offering Dividends & Price Growth
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
